Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model

被引:25
作者
Mouchess, Maria L.
Sohara, Yasuyoshi
Nelson, Marvin D., Jr.
DeClerck, Yves A.
Moats, Rex A.
机构
[1] Univ So Calif, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90089 USA
[2] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA USA
[3] Univ So Calif, Dept Radiol, Los Angeles, CA USA
[4] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA
关键词
D O I
10.1097/00004728-200605000-00030
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: This study evaluates the use of multimodal imaging to qualitatively and quantitatively measure tumor progression and bone resorption in a xenotransplanted tumor model of human neuroblastoma. Methods: Human neuroblastoma cells expressing a luciferase reporter gene were injected into the femur of nu/nu mice. Tumor progression with and without zoledronic acid treatment was monitored using radiographs, D-luciferin-induced luminescence, micro-computer tomography (CT) and micro-magnetic resonance imaging (MRI). Results: We observed a gradual increase in D-luciferin-based bioluminescence concomitant with detectable osteolytic lesions. Tumor growth was inhibited (P = 0.003-0.07) with zoledronic acid treatment. Micro-CT analysis in vivo provided a method to quantify bone loss, and its prevention by zoledronic acid. High-resolution MRI images allowed the observation of tumor cells within the bone marrow cavity, as well as distant metastasis. Conclusion: Multimodal imaging allows to measure tumor growth and bone resorption simultaneously in vivo and also proved useful in the detection of distant metastasis.
引用
收藏
页码:525 / 534
页数:10
相关论文
共 38 条
[1]   Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging [J].
Adams, JY ;
Johnson, M ;
Sato, M ;
Berger, F ;
Gambhir, SS ;
Carey, M ;
Iruela-Arispe, ML ;
Wu, L .
NATURE MEDICINE, 2002, 8 (08) :891-896
[2]  
Alvarez E, 2003, CLIN CANCER RES, V9, P5705
[3]   Moving disease biology from the lab to the clinic [J].
Anderson, KC .
CANCER, 2003, 97 (03) :796-801
[4]   A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].
Bekker, PJ ;
Holloway, DL ;
Rasmussen, AS ;
Murphy, R ;
Martin, SW ;
Leese, PT ;
Holmes, GB ;
Dunstan, CR ;
DePaoli, AM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066
[5]  
Body JJ, 1997, CANCER, V80, P1699, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.3.CO
[6]  
2-A
[7]   The antitumor potential of bisphosphonates [J].
Clézardin, P .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :33-42
[8]   Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival [J].
Croucher, PI ;
De Raeve, H ;
Perry, MJ ;
Hijzen, A ;
Shipman, CM ;
Lippitt, J ;
Green, J ;
Van Marck, E ;
Van Camp, B ;
Vanderkerken, K .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (03) :482-492
[9]   Antitumor effects of bisphosphonates [J].
Green, JR .
CANCER, 2003, 97 (03) :840-847
[10]   Spying on cancer: Molecular imaging in vivo with genetically encoded reporters [J].
Gross, S ;
Piwnica-Worms, D .
CANCER CELL, 2005, 7 (01) :5-15